Drug Trial Radar · NCT02366143
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Sep 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,202
Actual
Start
Mar 31, 2015
Primary completion
Sep 13, 2019
Study completion Dec 7, 2020
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibodyDrug
Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
BevacizumabDrug
Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
CarboplatinDrug
Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
PaclitaxelDrug
Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT PopulationTime frame: Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)
- Overall Survival (OS) in Arm B Versus Arm C in ITT-WT PopulationTime frame: Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)
- Overall Survival (OS) in Arm A Versus Arm C in ITT-WT PopulationTime frame: Baseline until death (up approximately 53 months)
Locations
240 sites in 26 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers
Chandler, Arizona
Arizona Oncology Associates
Flagstaff, Arizona
Southern CA Permanente Med Grp
Bellflower, California
Marin Cancer Care Inc
Greenbrae, California
Scripps Health
La Jolla, California
Chao Family Comprehensive Cancer Center UCI
Orange, California
Rocky Mountain Cancer Center
Denver, Colorado
Kaiser Permanente
Lonetree, Colorado
Danbury Hospital
Danbury, Connecticut
Yale Cancer Center
New Haven, Connecticut
Holy Cross Hospital Inc
Fort Lauderdale, Florida
Cancer Specialists of North Florida - Baptist South
Jacksonville, Florida
Mount Sinai Medical Center
Miami Beach, Florida
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida
Piedmont Cancer Institute, PC
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Univ of Chicago
Chicago, Illinois
Ingalls Memorial Hospital
Harvey, Illinois
Oncology Specialists, S.C.
Park Ridge, Illinois
Hematology-Oncology; Associates of the Quad Cities
Bettendorf, Iowa
Norton Cancer Institute
Louisville, Kentucky
New England Cancer Specialists
Scarborough, Maine
Mercy Medical Center
Baltimore, Maryland
Regional Cancer Care Associates
Bethesda, Maryland
Maryland Oncology Hematology, P.A.
Columbia, Maryland
St. Joseph Mercy Health System
Ann Arbor, Michigan
St. Luke's Regional Cancer Center
Duluth, Minnesota
Park Nicolett - Frauenshuh Cancer Center
Saint Louis Park, Minnesota
St. Luke's Cancer Institute
Kansas City, Missouri
Missouri Baptist Medical Center
St Louis, Missouri
Billings Clinic
Billings, Montana
Montana Cancer Specialists
Missoula, Montana
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
Summit Medical Group
Berkeley Heights, New Jersey
Valley Hospital; Oncology Research
Paramus, New Jersey
Regional Cancer Care Associates LLC
Sewell, New Jersey
Maimonides Medical Center
Brooklyn, New York
Montefiore Medical Center
The Bronx, New York
First Health of the Carolinas
Pinehurst, North Carolina
University of Cincinnati
Cincinnati, Ohio
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.